(SRT3) Sartorius Aktiengesellschaft - Overview
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE0007165631
Stock: Bioreactors, Filtration, Chromatography, Pipettes, Balances
Total Rating 44
Risk 78
Buy Signal -0.01
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.33% |
| Yield on Cost 5y | 0.16% |
| Yield CAGR 5y | 1.04% |
| Payout Consistency | 94.4% |
| Payout Ratio | 16.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 45.0% |
| Relative Tail Risk | -13.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.01 |
| Alpha | -12.45 |
| Character TTM | |
|---|---|
| Beta | 0.318 |
| Beta Downside | 0.456 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.43% |
| CAGR/Max DD | -0.30 |
Description: SRT3 Sartorius Aktiengesellschaft January 03, 2026
Sartorius Aktiengesellschaft (XETRA:SRT3) is a German-based provider of end-to-end bioprocess solutions and laboratory equipment. Its portfolio spans single-use and stainless-steel bioreactors, cell-culture media, high-throughput screening tools, filtration and chromatography consumables, live-cell imaging systems, and a suite of software for process automation, data analytics, and lab management. The company serves life-science research, biopharmaceutical manufacturing, cell- and gene-therapy production, and a range of applied industrial customers.
Key recent metrics (FY 2023) show revenue of roughly €5.2 billion, an operating margin of 16 % and a 9 % organic growth rate, primarily driven by rising demand for single-use bioprocessing hardware in the cell-therapy pipeline. Capital expenditures have risen to €350 million, reflecting expanded capacity in the companys filter-membrane and OEM divisions. A broader sector driver is the accelerated build-out of biologics manufacturing capacity worldwide, which is expected to sustain double-digit growth in the bioprocess equipment market through 2028.
For a data-rich, quantitative deep-dive on Sartorius’s valuation dynamics, the ValueRay platform offers a concise, model-backed view.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 169.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.09 > 1.0 |
| NWC/Revenue: -2.57% < 20% (prev 29.85%; Δ -32.42% < -1%) |
| CFO/TA 0.08 > 3% & CFO 727.4m > Net Income 169.2m |
| Net Debt (3.88b) to EBITDA (916.8m): 4.23 < 3 |
| Current Ratio: 0.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.0m) vs 12m ago 0.0% < -2% |
| Gross Margin: 46.48% > 18% (prev 0.44%; Δ 4605 % > 0.5%) |
| Asset Turnover: 36.25% > 50% (prev 33.94%; Δ 2.31% > 0%) |
| Interest Coverage Ratio: 2.20 > 6 (EBITDA TTM 916.8m / Interest Expense TTM 222.1m) |
Altman Z'' 1.51
| A: -0.01 (Total Current Assets 1.72b - Total Current Liabilities 1.81b) / Total Assets 9.61b |
| B: 0.24 (Retained Earnings 2.35b / Total Assets 9.61b) |
| C: 0.05 (EBIT TTM 488.2m / Avg Total Assets 9.70b) |
| D: 0.42 (Book Value of Equity 2.42b / Total Liabilities 5.80b) |
| Altman-Z'' Score: 1.51 = BB |
Beneish M -3.11
| DSRI: 0.98 (Receivables 344.7m/332.7m, Revenue 3.52b/3.32b) |
| GMI: 0.95 (GM 46.48% / 43.95%) |
| AQI: 0.99 (AQ_t 0.57 / AQ_t-1 0.57) |
| SGI: 1.06 (Revenue 3.52b / 3.32b) |
| TATA: -0.06 (NI 169.2m - CFO 727.4m) / TA 9.61b) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of SRT3 shares?
As of February 09, 2026, the stock is trading at EUR 239.60 with a total of 94,594 shares traded.
Over the past week, the price has changed by +1.61%, over one month by -9.55%, over three months by +7.25% and over the past year by -6.13%.
Over the past week, the price has changed by +1.61%, over one month by -9.55%, over three months by +7.25% and over the past year by -6.13%.
Is SRT3 a buy, sell or hold?
Sartorius Aktiengesellschaft has no consensus analysts rating.
What are the forecasts/targets for the SRT3 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 267.6 | 11.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 222.9 | -7% |
SRT3 Fundamental Data Overview January 31, 2026
Market Cap USD = 19.57b (16.58b EUR * 1.1801 EUR.USD)
P/E Trailing = 124.456
P/E Forward = 44.0529
P/S = 4.7147
P/B = 6.4764
P/EG = 1.0399
Revenue TTM = 3.52b EUR
EBIT TTM = 488.2m EUR
EBITDA TTM = 916.8m EUR
Long Term Debt = 3.24b EUR (from longTermDebt, last quarter)
Short Term Debt = 863.4m EUR (from shortTermDebt, last quarter)
Debt = 4.27b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.88b EUR (from netDebt column, last quarter)
Enterprise Value = 20.46b EUR (16.58b + Debt 4.27b - CCE 389.9m)
Interest Coverage Ratio = 2.20 (Ebit TTM 488.2m / Interest Expense TTM 222.1m)
EV/FCF = 61.69x (Enterprise Value 20.46b / FCF TTM 331.7m)
FCF Yield = 1.62% (FCF TTM 331.7m / Enterprise Value 20.46b)
FCF Margin = 9.43% (FCF TTM 331.7m / Revenue TTM 3.52b)
Net Margin = 4.81% (Net Income TTM 169.2m / Revenue TTM 3.52b)
Gross Margin = 46.48% ((Revenue TTM 3.52b - Cost of Revenue TTM 1.88b) / Revenue TTM)
Gross Margin QoQ = 46.63% (prev 47.07%)
Tobins Q-Ratio = 2.13 (Enterprise Value 20.46b / Total Assets 9.61b)
Interest Expense / Debt = 1.16% (Interest Expense 49.5m / Debt 4.27b)
Taxrate = 27.06% (23.0m / 85.0m)
NOPAT = 356.1m (EBIT 488.2m * (1 - 27.06%))
Current Ratio = 0.95 (Total Current Assets 1.72b / Total Current Liabilities 1.81b)
Debt / Equity = 1.60 (Debt 4.27b / totalStockholderEquity, last quarter 2.67b)
Debt / EBITDA = 4.23 (Net Debt 3.88b / EBITDA 916.8m)
Debt / FCF = 11.70 (Net Debt 3.88b / FCF TTM 331.7m)
Total Stockholder Equity = 2.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.74% (Net Income 169.2m / Total Assets 9.61b)
RoE = 6.27% (Net Income TTM 169.2m / Total Stockholder Equity 2.70b)
RoCE = 8.22% (EBIT 488.2m / Capital Employed (Equity 2.70b + L.T.Debt 3.24b))
RoIC = 5.00% (NOPAT 356.1m / Invested Capital 7.12b)
WACC = 5.81% (E(16.58b)/V(20.85b) * Re(7.09%) + D(4.27b)/V(20.85b) * Rd(1.16%) * (1-Tc(0.27)))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.45%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈376.9m ; Y1≈465.0m ; Y5≈791.9m
Fair Price DCF = 551.1 (EV 23.06b - Net Debt 3.88b = Equity 19.18b / Shares 34.8m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -80.71 | EPS CAGR: -16.67% | SUE: 0.07 | # QB: 0
Revenue Correlation: -62.27 | Revenue CAGR: -2.36% | SUE: 0.21 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.36 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=5.77 | Chg30d=-0.036 | Revisions Net=-4 | Growth EPS=+19.5% | Growth Revenue=+7.3%
P/E Trailing = 124.456
P/E Forward = 44.0529
P/S = 4.7147
P/B = 6.4764
P/EG = 1.0399
Revenue TTM = 3.52b EUR
EBIT TTM = 488.2m EUR
EBITDA TTM = 916.8m EUR
Long Term Debt = 3.24b EUR (from longTermDebt, last quarter)
Short Term Debt = 863.4m EUR (from shortTermDebt, last quarter)
Debt = 4.27b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.88b EUR (from netDebt column, last quarter)
Enterprise Value = 20.46b EUR (16.58b + Debt 4.27b - CCE 389.9m)
Interest Coverage Ratio = 2.20 (Ebit TTM 488.2m / Interest Expense TTM 222.1m)
EV/FCF = 61.69x (Enterprise Value 20.46b / FCF TTM 331.7m)
FCF Yield = 1.62% (FCF TTM 331.7m / Enterprise Value 20.46b)
FCF Margin = 9.43% (FCF TTM 331.7m / Revenue TTM 3.52b)
Net Margin = 4.81% (Net Income TTM 169.2m / Revenue TTM 3.52b)
Gross Margin = 46.48% ((Revenue TTM 3.52b - Cost of Revenue TTM 1.88b) / Revenue TTM)
Gross Margin QoQ = 46.63% (prev 47.07%)
Tobins Q-Ratio = 2.13 (Enterprise Value 20.46b / Total Assets 9.61b)
Interest Expense / Debt = 1.16% (Interest Expense 49.5m / Debt 4.27b)
Taxrate = 27.06% (23.0m / 85.0m)
NOPAT = 356.1m (EBIT 488.2m * (1 - 27.06%))
Current Ratio = 0.95 (Total Current Assets 1.72b / Total Current Liabilities 1.81b)
Debt / Equity = 1.60 (Debt 4.27b / totalStockholderEquity, last quarter 2.67b)
Debt / EBITDA = 4.23 (Net Debt 3.88b / EBITDA 916.8m)
Debt / FCF = 11.70 (Net Debt 3.88b / FCF TTM 331.7m)
Total Stockholder Equity = 2.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.74% (Net Income 169.2m / Total Assets 9.61b)
RoE = 6.27% (Net Income TTM 169.2m / Total Stockholder Equity 2.70b)
RoCE = 8.22% (EBIT 488.2m / Capital Employed (Equity 2.70b + L.T.Debt 3.24b))
RoIC = 5.00% (NOPAT 356.1m / Invested Capital 7.12b)
WACC = 5.81% (E(16.58b)/V(20.85b) * Re(7.09%) + D(4.27b)/V(20.85b) * Rd(1.16%) * (1-Tc(0.27)))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.45%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈376.9m ; Y1≈465.0m ; Y5≈791.9m
Fair Price DCF = 551.1 (EV 23.06b - Net Debt 3.88b = Equity 19.18b / Shares 34.8m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -80.71 | EPS CAGR: -16.67% | SUE: 0.07 | # QB: 0
Revenue Correlation: -62.27 | Revenue CAGR: -2.36% | SUE: 0.21 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.36 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=5.77 | Chg30d=-0.036 | Revisions Net=-4 | Growth EPS=+19.5% | Growth Revenue=+7.3%